# Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Source: https://onco.cc/trials/nct06380751/  
OnCo record `nct06380751` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Saruparib, Camizestrant, Abemaciclib, Ribociclib, Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.

## Summary

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer is a phase 3 interventional study registered as NCT06380751 by AstraZeneca, with 788 participants planned, started 2024-08-01 and due to reach its primary completion in 2029-12-18. Interventions recorded: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib and Fulvestrant.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06380751
- Phase: 3
- Setting: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
- Sponsor: AstraZeneca
- Enrolled: 788

## Sources

- ClinicalTrials.gov NCT06380751: https://clinicaltrials.gov/study/NCT06380751

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Camizestrant](https://onco.cc/drugs/camizestrant/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Ribociclib](https://onco.cc/drugs/ribociclib/), [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06380751.json